Zobrazeno 1 - 10
of 29
pro vyhledávání: '"José Luis Manzano"'
Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
Autor:
Sofia España Fernandez, Chen Sun, Carme Solé-Blanch, Aram Boada, Anna Martínez-Cardús, José Luis Manzano
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 823 (2023)
Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum previously u
Externí odkaz:
https://doaj.org/article/b6f78230cf9a4065b82322977530907c
Autor:
Núria Mulet-Margalef, Jenniffer Linares, Jordi Badia-Ramentol, Mireya Jimeno, Carolina Sanz Monte, José Luis Manzano Mozo, Alexandre Calon
Publikováno v:
Cancers, Vol 15, Iss 4, p 1022 (2023)
About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability–high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and in contrast to other colore
Externí odkaz:
https://doaj.org/article/fe5520b10fb646f19a9011fcca9b515c
Autor:
Gabriela Antelo, Cinta Hierro, Juan Pablo Fernández, Eduardo Baena, Cristina Bugés, Laura Layos, José Luis Manzano, Mónica Caro, Ricard Mesia
Publikováno v:
Drugs in Context, Vol 9, Pp 1-13 (2020)
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumours, which can be classified into neuroendocrine tumours (NETs), neuroendocrine carcinomas (NECs) and mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs). To date, there is
Externí odkaz:
https://doaj.org/article/5dde89858f5c4490bf582d81d485bda4
Autor:
José Luis Manzano, Ivan Marquez-Rodas, Cristina Carrera, Mario Mandala, Eva Muñoz-Couselo, Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, Carolina Ortiz, Roger Paredes, Daniel Podzamczer, Jose Molto, Boris Revollo, Lourdes Mateu, Sara Fancelli, Enrique Espinosa, Bonaventura Clotet, Javier Martinez-Picado, Pablo Cerezuela, Ainara Soria, Alfonso Berrocal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumo
Externí odkaz:
https://doaj.org/article/9b4da5993e134c378f9c571d2ea5242c
Autor:
Vicenç Ruiz de Porras, Sara Bystrup, Sara Cabrero-de las Heras, Eva Musulén, Luis Palomero, Maria Henar Alonso, Rocio Nieto, Diego Arango, Víctor Moreno, Cristina Queralt, José Luis Manzano, Laura Layos, Cristina Bugés, Eva Martinez-Balibrea
Publikováno v:
Cancers, Vol 11, Iss 10, p 1540 (2019)
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pat
Externí odkaz:
https://doaj.org/article/2b11169517424677a0f37a52b1a8612a
Autor:
Alba Ginés, Sara Bystrup, Vicenç Ruiz de Porras, Cristina Guardia, Eva Musulén, Anna Martínez-Cardús, José Luis Manzano, Laura Layos, Albert Abad, Eva Martínez-Balibrea
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0123830 (2015)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplati
Externí odkaz:
https://doaj.org/article/db9b14ae152947aa823c7a183722175b
Autor:
Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Margarita Reboredo, José Luis Manzano, Fernando Rivera, M José Safont, Clara Montagut, Encarnación González, Manuel Benavides, Eugenio Marcuello, Andrés Cervantes, Purificación Martínez de Prado, Carlos Fernández-Martos, Antonio Arrivi, Inmaculada Bando, Enrique Aranda, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e47345 (2012)
In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab
Externí odkaz:
https://doaj.org/article/326f07e214c74b4f9ed391316b89d17c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maria, Gonzalez-Cao, Teresa, Puertolas, Clara, Martinez-Vila, Cristina, Carrera, Cayetana, Maldonado Seral, Pedro, Rodríguez-Jiménez, Silvia, Sequero, Pablo, Cerezuela-Fuentes, Rosa, Feltes Ochoa, Eva, Muñoz, Mónica, Antoñanzas Basa, Juan, Martín-Liberal, Ainara, Soria, Juan, Francisco Rodriguez Moreno, Ivan, Marquez-Rodas, Pilar, Lopez Criado, José, Luis Manzano, Rafael, Lopez-Castro, Pablo, Ayala de Miguel, Laura, Villalobos, Salvador, Martin Algarra, Ines, Gonzalez-Barrallo, Aram, Boada, Almudena, García Castaño, Susana, Puig, Guillermo, Crespo, Pablo, Luna Fra, Cristina, Aguayo Zamora, Marta, Feito Rodríguez, Lara, Valles, Ana, Drozdowskyj, Jesús, Gardeazabal, Luis, Antonio Fernandez-Morales, Alberto, Rodrigo, Raquel, Cruz, Oriol, Yelamos, Belen, Rubio, Karmele, Mujica, Mariano, Provencio, Alfonso, Berrocal
Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ( GRAVID ).Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pande
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::0f3f41e0e5a020dbbf18dbcc0d240b01
https://hdl.handle.net/10171/65982
https://hdl.handle.net/10171/65982
Autor:
Maria Fabregat‐Pratdepadua, Aram Boada, José Luis Manzano, Isabel Bielsa, Júlia Verdaguer‐Faja, Ariadna Quer Pi‐Sunyer, José‐Manuel Carrascosa
Publikováno v:
Australasian Journal of Dermatology. 63:269-271